Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of DKK 74.26 billion. The enterprise value is 54.19 billion.

Market Cap	74.26B
Enterprise Value	54.19B

Important Dates

The next estimated earnings date is Thursday, May 8, 2025.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Genmab has 63.55 million shares outstanding. The number of shares has decreased by -1.95% in one year.

Current Share Class	n/a
Shares Outstanding	63.55M
Shares Change (YoY)	-1.95%
Shares Change (QoQ)	+0.39%
Owned by Insiders (%)	1.08%
Owned by Institutions (%)	52.96%
Float	62.86M

Valuation Ratios

The trailing PE ratio is 9.63 and the forward PE ratio is 11.30. Genmab's PEG ratio is 2.35.

PE Ratio	9.63
Forward PE	11.30
PS Ratio	3.48
PB Ratio	2.02
P/TBV Ratio	3.40
P/FCF Ratio	9.79
P/OCF Ratio	n/a
PEG Ratio	2.35

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.23, with an EV/FCF ratio of 7.14.

EV / Earnings	6.91
EV / Sales	2.52
EV / EBITDA	7.23
EV / EBIT	7.65
EV / FCF	7.14

Financial Position

The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.03.

Current Ratio	5.25
Quick Ratio	5.24
Debt / Equity	0.03
Debt / EBITDA	0.14
Debt / FCF	0.14
Interest Coverage	58.99

Financial Efficiency

Return on equity (ROE) is 22.97% and return on invested capital (ROIC) is 12.62%.

Return on Equity (ROE)	22.97%
Return on Assets (ROA)	10.91%
Return on Invested Capital (ROIC)	12.62%
Return on Capital Employed (ROCE)	17.48%
Revenue Per Employee	8.03M
Profits Per Employee	2.92M
Employee Count	2,682
Asset Turnover	0.53
Inventory Turnover	16.55

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -40.58% in the last 52 weeks. The beta is 0.96, so Genmab's price volatility has been similar to the market average.

Beta (5Y)	0.96
52-Week Price Change	-40.58%
50-Day Moving Average	1,432.66
200-Day Moving Average	1,600.91
Relative Strength Index (RSI)	35.00
Average Volume (20 Days)	214,564

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of DKK 21.53 billion and earned 7.84 billion in profits. Earnings per share was 121.36.

Revenue	21.53B
Gross Profit	20.54B
Operating Income	7.08B
Pretax Income	9.16B
Net Income	7.84B
EBITDA	7.39B
EBIT	7.08B
Earnings Per Share (EPS)	121.36

Full Income Statement

Balance Sheet

The company has 21.10 billion in cash and 1.03 billion in debt, giving a net cash position of 20.07 billion or 315.84 per share.

Cash & Cash Equivalents	21.10B
Total Debt	1.03B
Net Cash	20.07B
Net Cash Per Share	315.84
Equity (Book Value)	36.70B
Book Value Per Share	577.54
Working Capital	22.55B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.77 billion and capital expenditures -187.00 million, giving a free cash flow of 7.58 billion.

Operating Cash Flow	7.77B
Capital Expenditures	-187.00M
Free Cash Flow	7.58B
FCF Per Share	119.34

Full Cash Flow Statement

Margins

Gross margin is 95.42%, with operating and profit margins of 32.89% and 36.44%.

Gross Margin	95.42%
Operating Margin	32.89%
Pretax Margin	42.57%
Profit Margin	36.44%
EBITDA Margin	34.33%
EBIT Margin	32.89%
FCF Margin	35.23%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.95%
Shareholder Yield	1.95%
Earnings Yield	10.56%
FCF Yield	10.21%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 10.02.

Altman Z-Score	10.02
Piotroski F-Score	n/a